Two abstracts show the potential for using Veracyte’s tools to characterize the tumor microenvironment

Veracyte, Inc. (Nasdaq: VCYT) today announced that two poster presentations taking place at SITC 2023, the annual meeting of the Society for Immunotherapy of Cancer, in San Diego from November 3-5 will demonstrate the potential for using the company’s novel tools to help advance the development of immuno-oncology drugs. These tools allow for better characterization of the tumor microenvironment (TME), which can enable new insights into drug response and mechanisms of resistance.

“While immunotherapy drugs such as immune checkpoint inhibitors have been shown to induce remarkable, long-term responses in many cancer types, they remain ineffective for a majority of patients. There is a pressing need to understand drug response so scientists can develop treatments that will be effective for many more patients and types of cancer,” said Corinne Danan, Veracyte’s general manager of Biopharma and IVD Services. “These conference presentations will show that Veracyte’s Brightplex and Immunoscore IC tools can offer scientists a clearer view of the tumor microenvironment, as well as data that could inform immuno-oncology drug development.”

The following posters will be presented at the SITC 2023 meeting on Saturday, November 4, 2023:

Title: Deciphering the relationship between lymphocytes and macrophages within the tumor micro-environment using a workflow combining RNA transcripts detection and multiplex IHC on Brightplex®

Presenter: Jacques Fieschi, Ph.D., VP, research and development, Veracyte

Abstract: #70

Location: Exhibit Halls A and B1

Title: Regulatory T-cell tumor infiltration improves advanced NSCLC patients’ outcome under ≥ 2nd line anti-PD1/L1monotherapy in The PIONeeR Project

Presenter: Florence Monville, Ph.D., Scientific Head of Collaborative Research Projects at Veracyte

Abstract: #782-C

Location: Exhibit Hall B

In addition, Veracyte will host the following corporate symposium on Friday, November 3, 2023, from 5:10 p.m. to 6:40 p.m. PT:

Title: A Promising Biomarker of Tumor Immunogenicity: Unveiling the Potential of Immunoscore IC® (CD8/PDL1)

Presenters: Jérôme Galon, Ph.D. (scientific executive director, Veracyte); Jacques Fieschi, Ph.D. (VP, research and development, Veracyte)

Location: Presentation Stage (Exhibition Floor)

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that Veracyte’s Brightplex and Immunoscore IC tools can offer scientists a clearer view of the tumor microenvironment, as well as data that could inform immuno-oncology drug development. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2023. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, Brightplex, and Immunoscore IC are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. Brightplex and Immunoscore IC are available for clinical research. Those tests have not been cleared nor approved by the FDA and are not for use in diagnostic procedures.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231027584682/en/